RECRUITINGOBSERVATIONAL
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
About This Trial
This study aims to synthesise PET data that preserves biological relevance and adds clinical value to the diagnosis and prognosis of lung cancer by establishing anatomical-to-metabolic mapping based on paired diagnostic CT and FDG-PET scans, thereby prospectively validating the clinical utility of the model.
Who May Be Eligible (Plain English)
Who May Qualify:
1. Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;
2. Voluntarily participate and sign an willing to sign a consent form form;
Who Should NOT Join This Trial:
1. History of other malignant tumours;
2. Image artefacts;
3. Without pathological diagnostic information;
4. Without paired CT and FDG-PET scan images.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. Patients with non-small cell lung cancer scheduled to undergo PET-CT and pathological examinations;
2. Voluntarily participate and sign an informed consent form;
Exclusion Criteria:
1. History of other malignant tumours;
2. Image artefacts;
3. Without pathological diagnostic information;
4. Without paired CT and FDG-PET scan images.
Treatments Being Tested
DIAGNOSTIC_TEST
PET-CT
A PET-CT scan is performed prior to initiating systemic treatment for the tumour.
Locations (5)
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Ningbo No.2 Hospital
Ningbo, Zhejiang, China